摘要
目的探究阿托伐他汀钙联合奥氮平治疗阿尔茨海默病(AD)患者的临床效果及对患者脂代谢水平及痴呆病理行为的影响。方法回顾性分析2019年3月至2021年4月宜春市第三人民医院收治的68例AD患者的临床资料,根据治疗方案不同分为阿托伐他汀钙组(n=33)与研究组(n=35)。阿托伐他汀钙组给予阿托伐他汀钙治疗,研究组给予阿托伐他汀钙联合奥氮平治疗,比较两组治疗前后脂代谢水平、痴呆病理行为评定表(BEHAVE-AD)评分及不同时间简易精神状况量表(MMSE)评分及不良反应发生率。结果治疗后,两组载脂蛋白AⅠ(apoAⅠ)、总胆固醇(TC)、三酰甘油(TG)均低于治疗前,载脂蛋白B(apoB)水平均高于治疗前(P<0.05),但两组比较差异无统计学意义。治疗后,两组偏执与幻想、幻觉、行为紊乱、攻击行为、日夜节律紊乱、情感障碍、焦虑和恐惧评分均低于治疗前,且研究组低于阿托伐他汀钙组,差异有统计学意义(P<0.05)。两组MMSE评分组间、交互比较差异无统计学意义,两组MMSE评分时间比较差异有统计学意义(P<0.05)。组内比较:随访结束时,研究组MMSE评分高于初诊时、出院时,差异有统计学意义(P<0.05),其余两两组内比较差异无统计学意义。组间比较:初诊时、出院时,两组MMSE评分比较差异无统计学意义;随访结束时,研究组MMSE评分高于阿托伐他汀钙组,差异有统计学意义(P<0.05)。两组不良反应发生率比较差异无统计学意义。结论阿托伐他汀钙联合奥氮平治疗阿尔茨海默病疗效确切,可改善患者血脂代谢及精神行为症状,提高其认知功能,且安全性较高。
Objective To explore the clinical effect of atorvastatin calcium combined with olanzapine in the treatment of patients with Alzheimer's disease(AD)and its influence on lipid metabolism and pathological behavior of dementia.Methods The clinical data of 68 patients with AD admitted to the Third People's Hospital of Yichun from March 2019 to April 2021 were retrospectively analyzed,they were divided into the atorvastatin calcium group(n=33)and the study group(n=35)according to different treatment regimens.The atorvastatin calcium group was treated with atorvastatin calcium,while the study group was given atorvastatin calcium combined with olanzapine.Lipid metabolism and behavioral pathology in Alzheimer's disease scale(BEHAVE-AD)scores before and after treatment,Mini-Mental State Examination(MMSE)score at different time points and incidence rates of adverse reactions were compared between groups.Results After treatment,the levels of apolipoprotein AⅠ(apoAⅠ),total cholesterol(TC)and triacylglycerol(TG)of the two groups were lower than those before treatment,while the level of apolipoprotein B(apoB)was higher than that before treatment(P<0.05),but there were no statistical differences between the two groups.After treatment,the scores of paranoia and fantasy,hallucination,behavioral disorder,aggressive behavior,circadian rhythm disorder,emotional disorder,anxiety and fear of two groups were lower compared with those before treatment,and the study group were lower than those in the atorvastatin calcium group,and the differences were statistically significant(P<0.05).There were no significant differences of MMSE score between the two groups of group and interaction,there were significant differences of MMSE score between two groups of time points(P<0.05).Comparison within group:at the end of follow-up,the MMSE score of the study group was higher than that at the time of initial diagnosis and discharge,and the difference was statistically significant(P<0.05),there was no significant difference between the other two groups.Comparison between groups:at the time of initial diagnosis and discharge,there was no significant difference in MMSE score between the two groups;at the end of follow-up,the MMSE score in the study group was higher than that in the atorvastatin calcium group,and the difference was statistically significant(P<0.05).There were no statistical differences in the incidence rates of adverse reactions between both groups.Conclusion Atorvastatin calcium combined with olanzapine can improve blood lipid metabolism and mental and behavioral symptoms and enhance cognitive function in treating Alzheimer's disease,and has high safety.
作者
徐伟
余慧珍
涂环
XU Wei;YU Huizhen;TU Huan(The Third People's Hospital of Yichun,Yichun,Jiangxi,336000,China)
出处
《当代医学》
2023年第29期32-35,共4页
Contemporary Medicine
关键词
阿托伐他汀钙
奥氮平
阿尔茨海默病
脂代谢
认知功能
Atorvastatin calcium
Olanzapine
Alzheimer's disease
Lipid metabolism
Cognitive function
